CN1578677A - 改良的治疗方案 - Google Patents

改良的治疗方案 Download PDF

Info

Publication number
CN1578677A
CN1578677A CNA028214358A CN02821435A CN1578677A CN 1578677 A CN1578677 A CN 1578677A CN A028214358 A CNA028214358 A CN A028214358A CN 02821435 A CN02821435 A CN 02821435A CN 1578677 A CN1578677 A CN 1578677A
Authority
CN
China
Prior art keywords
dose
day
dox
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028214358A
Other languages
English (en)
Chinese (zh)
Inventor
特蕾西·琼·布朗
理查德·马克·福克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
Meditech Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR7302A external-priority patent/AUPR730201A0/en
Priority claimed from AUPR9504A external-priority patent/AUPR950401A0/en
Application filed by Meditech Research Ltd filed Critical Meditech Research Ltd
Publication of CN1578677A publication Critical patent/CN1578677A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028214358A 2001-08-27 2002-08-27 改良的治疗方案 Pending CN1578677A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR7302A AUPR730201A0 (en) 2001-08-27 2001-08-27 Preventive treatment for toxic side-effects caused by chemotherapeutic agents
AUPR7302 2001-08-27
AUPR9504A AUPR950401A0 (en) 2001-12-13 2001-12-13 Methods for treatment
AUPR9504 2001-12-13

Publications (1)

Publication Number Publication Date
CN1578677A true CN1578677A (zh) 2005-02-09

Family

ID=25646785

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028214358A Pending CN1578677A (zh) 2001-08-27 2002-08-27 改良的治疗方案

Country Status (7)

Country Link
US (2) US20050042303A1 (enExample)
EP (1) EP1427447A4 (enExample)
JP (1) JP2005505540A (enExample)
CN (1) CN1578677A (enExample)
CA (1) CA2458856C (enExample)
MX (1) MXPA04001828A (enExample)
WO (1) WO2003018062A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1041209A1 (zh) 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US8937052B2 (en) * 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
WO2009033047A2 (en) * 2007-09-07 2009-03-12 University Of Chicago Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan
EP2832309B1 (en) 2013-07-31 2018-03-07 Biedermann Technologies GmbH & Co. KG Implant for bones or vertebrae with self-constrained flexibility
JP2020153712A (ja) * 2019-03-18 2020-09-24 ソニーセミコンダクタソリューションズ株式会社 電流生成回路および測距システム

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US410452A (en) * 1889-09-03 Liam wiiarton
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4665107A (en) * 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) * 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
AU643141B2 (en) * 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
AU739601B2 (en) * 1991-07-03 2001-10-18 Meditech Research Limited Use of hyaluronan in gene therapy
DE69231123T2 (de) * 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
CA2089621A1 (en) * 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
US5847002A (en) * 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
EP0871475A2 (en) * 1995-09-14 1998-10-21 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2189916C (en) * 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
US6232301B1 (en) * 1996-12-27 2001-05-15 Seikagaku Corporation Remedies for bladder disorders
DK0971961T3 (da) * 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) * 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
IT1303735B1 (it) * 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
HK1041209A1 (zh) * 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
PT1044977E (pt) * 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
IT1306643B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6620927B2 (en) * 2001-02-22 2003-09-16 Anika Therapeutics, Inc. Thiol-modified hyaluronan
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US8937052B2 (en) * 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES

Also Published As

Publication number Publication date
US20090306012A1 (en) 2009-12-10
EP1427447A4 (en) 2007-05-23
CA2458856C (en) 2011-02-15
JP2005505540A (ja) 2005-02-24
WO2003018062A1 (en) 2003-03-06
MXPA04001828A (es) 2005-03-07
EP1427447A1 (en) 2004-06-16
CA2458856A1 (en) 2003-03-06
US20050042303A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
US20090306012A1 (en) Therapeutic protocols
US11246876B2 (en) Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
Liu et al. The function of heme-regulated eIF2α kinase in murine iron homeostasis and macrophage maturation
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
CN1388760A (zh) 在疾病治疗中作为胞毒剂,药物预致敏剂和化学致敏剂的透明质酸
CN1674942A (zh) 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
CN1192678A (zh) 生物药剂组合物
CN1336828A (zh) 增强药物功效的组合物和方法
CN1688303A (zh) 用于抗血管发生疗法的四硫代钼酸四丙铵及相关化合物
Zhang et al. Doxorubicin-liposome combined with clodronate-liposome inhibits hepatocellular carcinoma through the depletion of macrophages and tumor cells
CN1713905A (zh) 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
JP2015518835A (ja) 癌幹細胞を標的とした癌ワクチン
US11576957B2 (en) Vaccine and therapeutic compositions comprising antigen-conjugated viral capsids
WO2022063134A1 (zh) Csf1r激酶抑制剂及其用途
JP2020504164A (ja) 急性骨髄性白血病の予防および処置
EP4031655A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
TW202435875A (zh) 治療神經膠質瘤之方法
JP7541054B2 (ja) 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
US20230256080A1 (en) Vaccine and therapeutic compositions comprising antigen-conjugated viral capsids
JP2016525530A (ja) 急性骨髄性白血病及び骨髄異形成症候群の処置のためのボラセルチブと組み合わせたデシタビン
AU2002325635B2 (en) Improved therapeutic protocols
US20120121535A1 (en) Agent for preventing recurrence of leukemia
AU2002325635A1 (en) Improved therapeutic protocols
CN119548501B (zh) Csf1r抑制剂的新用途和药物
WO2024137356A1 (en) Methods for treatment of bone marrow failure and related conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication